Alnylam Pharmaceuticals
ALNY
#709
Rank
HK$279.48 B
Marketcap
HK$2,093
Share price
-1.61%
Change (1 day)
-18.01%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): HK$29.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is HK$29.72. In 2025 the company made an earnings per share (EPS) of HK$14.11.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$29.55109.35%
2025HK$14.11
2023-HK$27.68-62%
2022-HK$72.8429.03%
2021-HK$56.45-3.36%
2020-HK$58.41-8.48%
2019-HK$63.827.67%
2018-HK$59.2739.74%
2017-HK$42.4212.94%
2016-HK$37.5638.84%
2015-HK$27.05-32.88%
2014-HK$40.30259.44%
2013-HK$11.21-31.25%
2012-HK$16.31

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
HK$55.04 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$20.07-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$333.45 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-HK$4.47-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-HK$5.72-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-HK$2.12-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$10.74-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
HK$6.35-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA